Fritz Kunz joins PregLem's Board of Directors

Geneva, Switzerland, 4 September 2008 - PregLem SA, a Swiss
biopharmaceutical company specialized in reproductive medicine, today
announced that Dr. Fritz Kunz has joined its Board of Directors.

Fritz Kunz has had a long career in senior management and board
positions in the Swiss pharma and medtech industry. A Swiss national
and a chemist by training, he spent two decades at Swiss
pharmaceutical company Sandoz (now Novartis), including as head of
two preclinical research units as well as the human resources
department. In the early 1990's he was head of finance at Stratec
Medical before serving as CEO of Institut Straumann, a Swiss
manufacturer of dental implants, from 1994 to 1998. Dr. Kunz has
served on the Board of Directors of several Swiss biopharma and
medtech companies, including Straumann Holding (1998-2001), Sentec
(since 2003) and Allevia (since 2007). A member of its Board of
Directors since 1998, he has since 2000 served as Chairman of the
Board of Speedel, a biopharma company (SWX: SPPN) specialized in
cardiovascular and metabolic diseases, whose shareholders last month
accepted a public tender offer by Novartis. In 2007 Dr. Kunz also
became Chairman of the Board of Kuros Biosurgery, a private Swiss
biomedical company developing novel injectable materials for
localized therapies.

"I am delighted to join PregLem's Board of Directors," said Fritz
Kunz. "The company has an exciting pipeline addressing unmet needs in
major female reproductive health indications, with its lead product
now in phase III trials. I look forward to contributing to PregLem's
successful future development."

"Fritz Kunz brings with him extensive experience and an excellent
track record in working with innovative biopharma and medtech
companies to increase their value," commented Werner Henrich,
Chairman of PregLem's Board of Directors. "We are very glad to have
him on board."

About PregLem
PregLem SA is a Swiss specialty biopharmaceutical company focused on
the development and commercialization of innovative compounds for the
treatment of major benign gynecological conditions as well as
infertility. PregLem currently has four products in clinical and
pre-clinical development. Its most advanced product, PGL4001,
in-licensed from French pharmaceutical company HRA Pharma, entered
Phase III clinical trials in August 2008 for the treatment of uterine
myoma, a highly common benign tumor in women of reproductive age.
PregLem raised CHF 68 million from leading life science investors in
Series A and B funding rounds in 2007. The company obtained SME
status from the European Medicines Agency (EMEA) in November 2007.
PregLem was founded in Geneva in 2006 by Ernest Loumaye and Eric
Rolin.

More information is available at www.preglem.com.

For further information, please contact:

Solveig Hole, PregLem CEO office, Tel: +41 22 884 03 40, Email:
solveig.hole@preglem.com

Dr. Jonathan Leighton, Leighton Communications, Tel: +41 76 559 67
88, Email: jonl@sunrise.ch
Copyright © Hugin AS 2008. All rights reserved.